Treatment of decreased bone mineral density with zinc and ring finger 3 (ZNRF3) inhibitors

Patent metadata

Field	Value
Publication number	US-11713461-B2
Application number	US-202016907678-A
Country	US
Kind code	B2
Filing date	Jun 22, 2020
Priority date	Jun 21, 2019
Publication date	Aug 1, 2023
Grant date	Aug 1, 2023

Abstract

The present disclosure provides methods of treating patients having decreased bone mineral density, methods of identifying subjects having increased risk of developing decreased bone mineral density, methods of detecting human Zinc And Ring Finger 3 (ZNRF3) variant nucleic acid molecules and variant polypeptides, and ZNRF3 variant nucleic acid molecules and variant polypeptides.

First claim

What is claimed is:

1. A method of treating a patient with a therapeutic agent that treats or inhibits decreased bone mineral density, wherein the patient is suffering from decreased bone mineral density, the method comprising the steps of:
determining whether the patient has a Zinc And Ring Finger 3 (ZNRF3) predicted loss-of-function variant nucleic acid molecule encoding a human ZNRF3 polypeptide by:
obtaining or having obtained a biological sample from the patient; and
performing or having performed a genotyping assay on the biological sample to determine if the patient has a genotype comprising the ZNRF3 predicted loss-of-function variant nucleic acid molecule; and

when the patient is ZNRF3 reference, then administering or continuing to administer to the patient the therapeutic agent that treats or inhibits decreased bone mineral density in a standard dosage amount, and administering to the patient a ZNRF3 inhibitor; and
when the patient is heterozygous for a ZNRF3 predicted loss-of-function variant, then administering or continuing to administer to the patient the therapeutic agent that treats or inhibits decreased bone mineral density in an amount that is the same as or lower than a standard dosage amount, and administering to the patient a ZNRF3 inhibitor;
wherein the presence of a genotype having the ZNRF3 predicted loss-of-function variant nucleic acid molecule encoding the human ZNRF3 polypeptide indicates the patient has a reduced risk of developing decreased bone mineral density; and
wherein the ZNRF3 predicted loss-of-function variant is: a genomic nucleic acid molecule having a nucleotide sequence comprising a deletion of the position corresponding to position 167,122 according to SEQ ID NO:1; an mRNA molecule having a nucleotide sequence comprising a deletion of the position corresponding to position 2,707 according to SEQ ID NO:4, or a deletion of the position corresponding to position 2,397 according to SEQ ID NO:5; a cDNA molecule produced from an mRNA molecule in the biological sample, wherein the cDNA molecule has a nucleotide sequence comprising a deletion of the position corresponding to position 2,707 according to SEQ ID NO:10, or a deletion of the position corresponding to positions 2,397 according to SEQ ID NO:11; a genomic nucleic acid molecule having a nucleotide sequence comprising a guanine at a position corresponding to position 166,500 according to SEQ ID NO:3; an mRNA molecule having a nucleotide sequence comprising a guanine at a position corresponding to position 2,085 according to SEQ ID NO:8, or a guanine at a position corresponding to positions 1,175 according to SEQ ID NO:9; or a cDNA molecule produced from an mRNA molecule in the biological sample, wherein the cDNA molecule has a nucleotide sequence comprising a guanine at a position corresponding to position 2,085 according to SEQ ID NO:14, or a guanine at a position corresponding to position 1,175 according to SEQ ID NO:15.

2. The method according to claim 1 , wherein the patient has or is suspected of having osteopenia.

3. The method according to claim 1 , wherein the patient has or is suspected of having osteoporosis.

4. The method according to claim 1 , wherein the ZNRF3 inhibitor comprises an antisense nucleic acid molecule, a small interfering RNA (siRNA), or a short hairpin RNA (shRNA) that hybridizes to a ZNRF3 mRNA.

5. The method according to claim 1 , wherein the ZNRF3 inhibitor comprises an antisense nucleic acid molecule that hybridizes to a ZNRF3 mRNA.

6. The method according to claim 1 , wherein the ZNRF3 inhibitor comprises an siRNA that hybridizes to a ZNRF3 mRNA.

7. The method according to claim 1 , wherein the ZNRF3 inhibitor comprises a Cas protein and guide RNA (gRNA) that hybridizes to a gRNA recognition sequence within a ZNRF3 genomic nucleic acid molecule.

8. The method according to claim 1 , wherein determining whether the patient has a ZNRF3 predicted loss-of-function variant nucleic acid molecule comprises detecting the presence or absence of a genomic nucleic acid molecule having a nucleotide sequence comprising a deletion of the position corresponding to position 167,122 according to SEQ ID NO:1.

9. The method according to claim 1 , wherein determining whether the patient has a ZNRF3 predicted loss-of-function variant nucleic acid molecule comprises detecting the presence or absence of an mRNA molecule having a nucleotide sequence comprising a deletion of the position corresponding to position 2,707 according to SEQ ID NO:4, or a deletion of the position corresponding to position 2,397 according to SEQ ID NO:5.

10. The method according to claim 1 , wherein determining whether the patient has a ZNRF3 predicted loss-of-function variant nucleic acid molecule comprises detecting the presence or absence of a cDNA molecule produced from an mRNA molecule in the biological sample, wherein the cDNA molecule has a nucleotide sequence comprising a deletion of the position corresponding to position 2,707 according to SEQ ID NO:10, or a deletion of the position corresponding to positions 2,397 according to SEQ ID NO:11.

11. The method according to claim 1 , wherein determining whether the patient has a ZNRF3 predicted loss-of-function variant nucleic acid molecule comprises detecting the presence or absence of a genomic nucleic acid molecule having a nucleotide sequence comprising a guanine at a position corresponding to position 166,500 according to SEQ ID NO:3.

12. The method according to claim 1 , wherein determining whether the patient has a ZNRF3 predicted loss-of-function variant nucleic acid molecule comprises detecting the presence or absence of an mRNA molecule having a nucleotide sequence comprising a guanine at a position corresponding to position 2,085 according to SEQ ID NO:8, or a guanine at a position corresponding to positions 1,175 according to SEQ ID NO:9.

13. The method according to claim 1 , wherein determining whether the patient has a ZNRF3 predicted loss-of-function variant nucleic acid molecule comprises detecting the presence or absence of a cDNA molecule produced from an mRNA molecule in the biological sample, wherein the cDNA molecule has a nucleotide sequence comprising a guanine at a position corresponding to position 2,085 according to SEQ ID NO:14, or a guanine at a position corresponding to position 1,175 according to SEQ ID NO:15.

14. The method according to claim 1 , wherein the genotyping assay comprises sequencing at least a portion of the nucleotide sequence of the ZNRF3 nucleic acid molecule, wherein the sequenced portion comprises: a position corresponding to position 167,122 according to SEQ ID NO:2, or any position 3′ thereto, or the complement thereof; a position corresponding to position 166,500 according to SEQ ID NO:3, or the complement thereof; a position corresponding to position 2,707 according to SEQ ID NO:6, or any position 3′ thereto, or the complement thereof; a position corresponding to position 2,397 according to SEQ ID NO:7, or any position 3′ thereto, or the complement thereof; a position corresponding to position 2,085 according to SEQ ID NO:8, or the complement thereof; a position corresponding to position 1,775 according to SEQ ID NO:9, or the complement thereof; a position corresponding to position 2,707 according to SEQ ID NO:12, or any position 3′ thereto, or the complement thereof; a position corresponding to position 2,397 according to SEQ ID NO:13, or any position 3′ thereto, or the complement thereof; a position corresponding to position 2,085 according to SEQ ID NO:14, or the complement thereof; or a position corresponding to position 1,775 according to SEQ ID NO:15, or the complem

Assignees

• Regeneron Pharma
• Univ Maryland
• Regeneran Pharmaceuticals Inc

Inventors

• Gong Da-Wei
• Gosalia Nehal
• Shuldiner Alan
• Van Hout Cristopher
• Perry James

Classifications

• C12N15/1137 Primary

  against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138) · CPC title

• A61P19/10

  for osteoporosis · CPC title

• C12Q1/6874

  involving nucleic acid arrays, e.g. sequencing by hybridisation · CPC title

• C07K14/47 Primary

  from mammals · CPC title

• A61P19/08

  for bone diseases, e.g. rachitism, Paget's disease · CPC title